The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info—it’s all here.

Press Release

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

SAN DIEGO, April 22, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on April 24, 2025, at 4:15 p.m. ET.

The Newsroom

Join Calidi Biotherapeutics’ Exclusive Live Investor Webinar and Q&A Session on April 24

Calidi Biotherapeutics is initiating GMP manufacturing at VetStem BioPharma, a veterinary and human regenerative medicine company in San Diego, CA

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

First-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cells

Calidi Biotherapeutics Announces the Appointment of Distinguished Biotech Innovator, Ewa Carrier, M.D., to Their Medical and Scientific Advisory Board

Calidi Biotherapeutics Announces Global Oncolytic Virus-based Immunotherapy License to VetStem Biopharma for its Pioneering Treatment of Cancer in the Veterinary Field

Calidi Biotherapeutics Announces The Appointment of Medical Oncologist and Expert in Oncolytic Immunotherapies, Dr. Dmitriy Zamarin to Their Scientific Advisory Board

Calidi Biotherapeutics Announces FDA Authorization of IND for a Phase 1 Clinical Trial of NeuroNova in Patients with Recurrent High-Grade Glioma

Calidi Biotherapeutics Announces Appointment of W.K. Alfred Yung, M.D., to its Medical Advisory Board

Calidi Biotherapeutics to Present at Jefferies Healthcare Conference

Calidi Biotherapeutics Granted US Patent for Proprietary Therapeutic Delivery Platform, Strengthening Company’s Intellectual Property Position in Immunotherapy

Calidi Biotherapeutics Announces Appointment of Alfonso "Chito" Zulueta, Former President of International for Eli Lilly, to Its Board of Directors

Calidi Biotherapeutics and Edoc Acquisition Corp. Agree to Merge and Create a Publicly Listed, Clinical-Stage Biotechnology Company Utilizing Stem Cell-Based Platforms to Revolutionize Oncolytic Virotherapies

33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

The Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.

Scientific Advisory Board Member Interview - Santosh Kesari, M.D./Ph.D.

Scientific Advisory Board Member Interview - Bernard Fox, Ph.D.

Scientific Advisory Board Member Interview - W.K. Alfred Yung, M.D.

Scientific Advisory Board Member Interview - Ashok Srivastava, M.D./Ph.D.

Big Biz TV - Stephen Thesing

Big Biz TV - Allan Camaisa

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

All Courses

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.